All patients will be in the same arm. Patients are going to have two 18F-FLT-TEP and two 18F-FDG-TEP : the first ones during the two weeks before the beginning of erlotinib and the second ones will occur during the second week after the initiation of erlotinib. The order of TEP is not definite : 18F-FLT-TEP may be planned first or reciprocally. A period of 48 hours must separate two TEP.

Non-small Cell Lung Cancer Metastatic or Non-small Cell Lung Cancer Recurrent

No EGFR Activating Mutation

Patients are going to have two 18F-FLT-TEP : one during the two weeks before the beginning of erlotinib and the second one will occur during the second week after the initiation of erlotinib.

18F-FLT-TEP

Patients are going to have two 18F-FDG-TEP : one during the two weeks before the beginning of erlotinib and the second one will occur during the second week after the initiation of erlotinib.

18F-FDG-TEP

University Hospital, Bordeaux

Army Hospital, Percy

University Hospital, Toulouse

University Hospital, Tours

University Hospital, Angers

University Hospital, Nancy

University Hospital, Rouen

Hospital, Créteil

Theranostic Tool During Erlotinib Treatment in Non-small Cell Lung Cancer Patient

Could Positon Emission Tomography With Radiolabelled 3'-Deoxy-3'-(18)F-Fluoro-L-Thymidine be a Theranostic Tool During Erlotinib Treatment in Non-small Cell Lung Cancer Patients ?

The primary endpoint is the correlation between tumour response to erlotinib assessed by morphological imaging by RECIST 1.1 at Day 56 (considered the gold standard) and the change in the uptake of 18F-FLT and 18F-FDG assessed by PET before and at Day 7 after initiation of erlotinib derived from criteria PERCIST. the Kappa test will be used.

The aim of this study will be to determine if health costs could be minimized by early prediction of response to erltinib therapy.

Créteil Hospital

Central Hospital, Nancy, France

A portion of the study blood sample collected for the HIVVR test will be banked for future HIV research using the HIVVR test. Specifically, this future research will involve the HIVVR test for additional cell associated markers relating to HIV pathogenesis including (for example) other markers of activation and senescence, apoptosis (programmed cell death) and chemokine receptors (for HIV tropism).

HIV Positive

Sutter Street Internal Medicine

Evaluation of a Blood Test to Measure Immune Function in HIV Positive People Compared With HIV Negative People

QuantiFERON® Monitor Test to Evaluate Immune Function in HIV Infected and Uninfected Control Study Subjects

How long will it take? One visit for about 1 hour with Dr. Gatpolintan and his Clinical Study Coordinator to answer questions, then about 10 minutes for a blood draw (nine blocks from Dr. Gatpolintan' office).

thymidine/atrofija

Theranostic Tool During Erlotinib Treatment in Non-small Cell Lung Cancer Patient

Evaluation of a Blood Test to Measure Immune Function in HIV Positive People Compared With HIV Negative People

Vispilnīgākā ārstniecības augu datu bāze, kuru atbalsta zinātne